CLYM Stock — Climb Bio Inc.: Cash, EV, Pipeline

Share price

$14.05

Market cap

$807.0M

Cash

$183.1M

Enterprise value

$623.9M

Balance sheet

Cash	$183.1M
Debt	$0.0M
Net cash	$183.1M
Enterprise value	$623.9M
Basic shares	57.4M shares
Fully diluted shares	69.0M shares
Fully diluted market cap	$969.9M
Cash per share	$3.19

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CLYM daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Sep 23, 2026	CLYM116	Phase 1	Healthy Volunteers	—
May 13 - Jun 24	Budoprutug	Phase 1	Systemic Lupus Erythematosus	—
Sep 12 - Oct 24	Budoprutug	Phase 2	Immune Thrombocytopenia (ITP); ITP; Biologics	—
Oct 13 - Nov 24	Budoprutug	Phase 2	Systemic Lupus Erthematosus	—
Nov 12 - Dec 24	budoprutug	Phase 2	Primary Membranous Nephropathy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

budoprutug

Phase 2 · Active Modality: monoclonal antibody (IV and SC formulations)

Target CD19

Partnerships Acelyrin (Alumis): asset purchase ($157.5M milestones, single-digit royalties, sublicense fees; milestone-payment dispute in Delaware Superior Court, filed Dec 2025). Cancer Research Technology (CRH): exclusive license ex-oncology (up to GBP 106.8M milestones; mid-single to high-single-digit royalties)

Indications

Primary membranous nephropathy (pMN) (Phase 2)
Immune thrombocytopenia (ITP) (Phase 1)
Systemic lupus erythematosus (SLE) (Phase 1)

Catalysts

— Q4 2026
— Q4 2026
— Q4 2026
— 2027

Status note Lead program. Orphan-drug designation (Jan 2023) and Fast Track (Apr 2026) for pMN. Phase 2 PrisMN (pMN) enrolling second cohort; Phase 1b/2a ITP and Phase 1b SLE enrolling; China SLE Phase 1b/2a dosing since Jun 2026. IV + high-concentration SC formulation in development.

CLYM116

Phase 1 · Active Modality: monoclonal antibody

Target APRIL

Partnerships Mabworks Biotech: exclusive license ex-Greater China ($9M upfront; up to $30M dev/reg milestones for first indication; up to $832M commercial; low-to-mid single-digit royalties; amended and restated Jul 2026)

Indications

IgA nephropathy (IgAN) (Phase 1)

Catalysts

— September 3, 2026
— Q3 2026
— 2027

Status note Phase 1 healthy-volunteer dosing completed June 2026; partner Mabworks running parallel Phase 1/2 in China (healthy volunteers and IgAN).

ETX-123

Stage not disclosed · Active Modality: small molecule (potassium channel opener)

Target Kv7.2/3

Status note Legacy lead program from the company's prior neuronal-excitability focus; development paused July 2023 and the company intends to seek a partner. Soft wind-down, not formally discontinued.

ETX-155

Stage not disclosed · Active

Status note Legacy/previous product candidate from the prior neuronal-excitability program; no active development stated in this filing.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Budoprutug
Lead indication	Immune Thrombocytopenia (ITP)
Lead phase	Phase 2
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07043946	Phase 2	Recruiting	Sponsor	CLYM	—	Immune Thrombocytopenia (ITP); ITP; Biologics	—
NCT07564596	Phase 2	Recruiting	Sponsor	CLYM	—	Systemic Lupus Erthematosus	—
NCT07096843	Phase 2	Recruiting	Sponsor	CLYM	—	Primary Membranous Nephropathy	—
NCT07011043	Phase 1	Recruiting	Sponsor	CLYM	—	Systemic Lupus Erythematosus	—
NCT07248865	Phase 1	Recruiting	Sponsor	CLYM	—	Healthy Volunteers	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Climb Bio, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	2,797,375	+1,267,700	1.35%	2026-08-14
ADAR1 Capital Management	822,649	+224,987	0.50%	2026-08-14
Sphera Biotech	483,747	+64,500	0.90%	2026-08-14
Ikarian Capital	300,000	+300,000	0.64%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CLYM — Climb Bio Inc.